Mutant monocyte chemoattractant protein-1 protein (7ND) inhibits osteoclast differentiation and reduces oral squamous carcinoma cell bone invasion
Authors:
Open Access
- 21 March 2018
- journal article
- research article
- Published by Spandidos Publications in Oncology Letters
- Vol. 15 (5) , 7760-7768
Abstract
The seven‑amino acid truncated (7ND) protein is an N‑terminal deletion mutant of monocyte chemoattractant protein‑1 (MCP‑1) and it functions as a dominant‑negative inhibitor. 7ND and wild‑type MCP‑1 form a heterodimer, which binds to MCP‑1 receptors and inhibits monocyte chemotaxis. In the present study, the 7ND protein was cloned, expressed and purified. An MTT assay revealed that the proliferation of oral squamous cell carcinoma (OSCC) SCC25 cells was not affected following 3 days of treatment with synthetic 7ND protein. Serial dilutions of the 7ND protein were tested for monocyte migration and osteoclast differentiation, and tartrate‑resistant acid phosphatase staining demonstrated that significantly fewer osteoclasts were differentiated from cluster of differentiation 14+ (CD14+) monocytes using magnetic activated cell sorting. Immunofluorescence confirmed these results and significantly less F‑actin staining was observed in 7ND‑treated osteoclasts. Furthermore, bone invasion was examined by subcutaneously injecting SCC25 cells into the area overlaying the calvariae of nude mice. The results demonstrated that the average tumor volume of SCC25 cells with 7ND protein was similar to the average volume of tumors formed by untreated SCC25 cells. Flow cytometric analysis suggested that the CD14+ subpopulation in the bone marrow of 7ND‑treated mice was reduced compared with that of untreated mice. Micro‑computed tomography imaging revealed significantly less bone resorption in the calvariae injected with SCC25 cells plus the 7ND protein. Taken together, the results of the present study demonstrated the potential therapeutic value of the 7ND protein. The 7ND MCP‑1 variant not only functions in vitro to inhibit osteoclast differentiation, but also reduces the progression of bone invasion by OSCC cells in vivo.Keywords
This publication has 23 references indexed in Scilit:
- Mutant MCP-1 protein delivery from layer-by-layer coatings on orthopedic implants to modulate inflammatory responseBiomaterials, 2013
- Mutant monocyte chemoattractant protein 1 protein attenuates migration of and inflammatory cytokine release by macrophages exposed to orthopedic implant wear particlesJournal of Biomedical Materials Research Part A, 2013
- Dominant Negative MCP‐1 Blocks Human Osteoclast DifferentiationJournal of Cellular Biochemistry, 2013
- Transforming growth factor-β1 treatment of oral cancer induces epithelial-mesenchymal transition and promotes bone invasion via enhanced activity of osteoclastsClinical & Experimental Metastasis, 2013
- Properties of 7ND-CCL2 are modulated upon fusion to FcProtein Engineering, Design and Selection, 2012
- Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: a review of mechanismsCancer and Metastasis Reviews, 2011
- Mutant MCP-1 therapy inhibits tumor angiogenesis and growth of malignant melanoma in miceBiochemical and Biophysical Research Communications, 2008
- MCP-1 Is Induced by Receptor Activator of Nuclear Factor-κB Ligand, Promotes Human Osteoclast Fusion, and Rescues Granulocyte Macrophage Colony-stimulating Factor Suppression of Osteoclast FormationJournal of Biological Chemistry, 2005
- New Anti–Monocyte Chemoattractant Protein-1 Gene Therapy Attenuates Atherosclerosis in Apolipoprotein E–Knockout MiceCirculation, 2001
- MCP-1: Structure/Activity AnalysisMethods, 1996